GU Cancers 2023 | miR371 to detect minimal residual disease (MRD) and early relapse of testicular tumors

Lucia Nappi, MD, University of British Columbia, Vancouver, Canada, provides an overview of a longitudinal evaluation of plasma miR371 to detect minimal residual disease and early relapse of germ cell tumors. Sensitivity, specificity, negative and positive predictive values (NPV, PPV) and AUC in predicting tumor recurrence were evaluated for miR371 and compared to the same operating characteristics of current gold standard diagnostic tests. With a median follow-up of 41 months, 101 patients with clinical stage I germ cell testicular cancer were included. 34.6% of patients experienced a disease relapse during follow-up, 62.8% of whom were positive with miR371. The specificity and PPV were 100%, sensitivity 62.8%, NPV 83.5% and AUC 0.81. No false positives were observed. Patients with positive post-orchiectomy miR371 had a significantly shorter relapse-free survival (RFS) versus patients with a negative post-orchiectomy miR371. Additionally, miR371 sensitivity correlated with tumor burden, time between tumor relapse and miRNA testing and histology. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.